Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Proteomic biomarkers and pathway analysis for progression to heart failure in three epidemiological representative cohorts

Dieden, Anna LU orcid ; Girerd, Nicolas ; Ottosson, Filip LU ; Molvin, John LU ; Pareek, Manan ; Melander, Olle LU orcid ; Bachus, Erasmus LU ; Råstam, Lennart LU ; Lindblad, Ulf and Daka, Bledar , et al. (2024) In European Journal of Heart Failure
Abstract

AIMS: Biomarkers associated with asymptomatic ventricular dysfunction might improve risk stratification and identify pathways leading to heart failure (HF). We explored the association between proteomic biomarkers and left ventricular hypertrophy (LVH), diastolic dysfunction (DD) and incident HF in three population-based cohorts.

METHODS AND RESULTS: A chip was used to measure 92 protein biomarkers in blood samples from >1500 Malmö Preventive Project (MPP) participants, of whom 514 had LVH (34%), 462 had DD (32.4%) and, over a median follow-up of 13 (11-14) years, 130 developed HF (7.7%). Findings were confirmed in the STANISLAS (n > 1500, 238 participants with LVH, 76 with DD) and HOMAGE case-control (562 cases of incident... (More)

AIMS: Biomarkers associated with asymptomatic ventricular dysfunction might improve risk stratification and identify pathways leading to heart failure (HF). We explored the association between proteomic biomarkers and left ventricular hypertrophy (LVH), diastolic dysfunction (DD) and incident HF in three population-based cohorts.

METHODS AND RESULTS: A chip was used to measure 92 protein biomarkers in blood samples from >1500 Malmö Preventive Project (MPP) participants, of whom 514 had LVH (34%), 462 had DD (32.4%) and, over a median follow-up of 13 (11-14) years, 130 developed HF (7.7%). Findings were confirmed in the STANISLAS (n > 1500, 238 participants with LVH, 76 with DD) and HOMAGE case-control (562 cases of incident HF, 871 controls) cohorts. In multivariable logistic or Cox regression analyses adjusted for age, sex and cardiovascular risk factors, N-terminal pro-B-type natriuretic peptide (NT-proBNP) was associated with LVH, DD and incident HF in all cohorts: MPP (LVH odds ratio [OR] [95% confidence interval] 1.48 [1.28-1.71]; DD OR 1.71 [1.53-1.92]; HF HR 1.98 [1.66-2.36]); STANISLAS (LVH OR 1.20 [1.02-1.41]; DD OR 1.46 [1.12-1.90]); HOMAGE (HF HR 1.85 [1.62-2.12]). Galectin-4, growth differentiation factor 15 and suppression of tumorigenicity-2 were associated with incident HF in MPP and HOMAGE. A pathway enrichment analysis suggested that inflammation and viral infection were related to incident HF.

CONCLUSION: In conclusion, our study reinforces the role of NT-proBNP as a key biomarker for asymptomatic cardiac dysfunction and incident HF, consistent with its established use in clinical practice. This underscores the value of NT-proBNP for identifying patients at high risk for HF, and provides insights into pathways leading to HF and potential therapeutic targets.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
epub
subject
in
European Journal of Heart Failure
publisher
Elsevier
external identifiers
  • scopus:85207916356
  • pmid:39466935
ISSN
1879-0844
DOI
10.1002/ejhf.3502
language
English
LU publication?
yes
additional info
© 2024 The Author(s). European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
id
0690a040-c0ea-4f7f-91c8-db48480800c2
date added to LUP
2024-11-04 09:27:55
date last changed
2025-07-09 23:51:20
@article{0690a040-c0ea-4f7f-91c8-db48480800c2,
  abstract     = {{<p>AIMS: Biomarkers associated with asymptomatic ventricular dysfunction might improve risk stratification and identify pathways leading to heart failure (HF). We explored the association between proteomic biomarkers and left ventricular hypertrophy (LVH), diastolic dysfunction (DD) and incident HF in three population-based cohorts.</p><p>METHODS AND RESULTS: A chip was used to measure 92 protein biomarkers in blood samples from &gt;1500 Malmö Preventive Project (MPP) participants, of whom 514 had LVH (34%), 462 had DD (32.4%) and, over a median follow-up of 13 (11-14) years, 130 developed HF (7.7%). Findings were confirmed in the STANISLAS (n &gt; 1500, 238 participants with LVH, 76 with DD) and HOMAGE case-control (562 cases of incident HF, 871 controls) cohorts. In multivariable logistic or Cox regression analyses adjusted for age, sex and cardiovascular risk factors, N-terminal pro-B-type natriuretic peptide (NT-proBNP) was associated with LVH, DD and incident HF in all cohorts: MPP (LVH odds ratio [OR] [95% confidence interval] 1.48 [1.28-1.71]; DD OR 1.71 [1.53-1.92]; HF HR 1.98 [1.66-2.36]); STANISLAS (LVH OR 1.20 [1.02-1.41]; DD OR 1.46 [1.12-1.90]); HOMAGE (HF HR 1.85 [1.62-2.12]). Galectin-4, growth differentiation factor 15 and suppression of tumorigenicity-2 were associated with incident HF in MPP and HOMAGE. A pathway enrichment analysis suggested that inflammation and viral infection were related to incident HF.</p><p>CONCLUSION: In conclusion, our study reinforces the role of NT-proBNP as a key biomarker for asymptomatic cardiac dysfunction and incident HF, consistent with its established use in clinical practice. This underscores the value of NT-proBNP for identifying patients at high risk for HF, and provides insights into pathways leading to HF and potential therapeutic targets.</p>}},
  author       = {{Dieden, Anna and Girerd, Nicolas and Ottosson, Filip and Molvin, John and Pareek, Manan and Melander, Olle and Bachus, Erasmus and Råstam, Lennart and Lindblad, Ulf and Daka, Bledar and Leósdóttir, Margrét and Nilsson, Peter M and Olsen, Michael H and Clark, Andrew L and Cleland, John G F and Delles, Christian and González, Arantxa and Lamiral, Zohra and Duarte, Kevin and Rossignol, Patrick and Zannad, Faiez and Gudmundsson, Petri and Jujić, Amra and Magnusson, Martin}},
  issn         = {{1879-0844}},
  language     = {{eng}},
  month        = {{10}},
  publisher    = {{Elsevier}},
  series       = {{European Journal of Heart Failure}},
  title        = {{Proteomic biomarkers and pathway analysis for progression to heart failure in three epidemiological representative cohorts}},
  url          = {{http://dx.doi.org/10.1002/ejhf.3502}},
  doi          = {{10.1002/ejhf.3502}},
  year         = {{2024}},
}